Skip to content

Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults

Wearable Technology to Reduce Sedentary Behavior and CVD Risk in Older Adults

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02632487
Enrollment
58
Registered
2015-12-16
Start date
2016-04-30
Completion date
2018-11-20
Last updated
2018-11-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Diseases

Brief summary

This study will evaluate the feasibility and efficacy of combining a traditional, structured exercise intervention with an innovative intervention designed to decrease sedentary behavior and increase non-exercise physical activity (NEPA).

Detailed description

A recruitment of 40 sedentary men and women ≥ 60 years of age with elevated cardiovascular risk and follow them for 20 weeks. Participants will be randomly assigned (n = 20/group) to 1) an 8-week, twice-weekly, multi-modal, center-based exercise intervention (EX) followed by 12 additional weeks of follow-up assessment, or 2) the same intervention with participants also asked to wear a validated lightweight activity tracker on their hip during waking hours and instructed on how to reduce sedentary behavior increase NEPA within their daily routines (EX + NEPA). Evaluations will be done to 1) the extent to which EX + NEPA modifies sedentary behavior, 2) the impact of the interventions on cardiovascular risk factors, including blood pressure, exercise capacity, waist circumference, and circulating biomarkers, and 3) develop and optimize study procedures to guide the future trial.

Interventions

BEHAVIORALExercise

Center-based walking + balance, stretching, and light resistance

BEHAVIORALNon-Exercise Physical Activity (NEPA)

Behavioral counseling paired with technology intervention to monitor physical activity

Sponsors

American Heart Association
CollaboratorOTHER
University of Florida
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Sedentary lifestyle, defined as \<150 min/wk of moderate physical activity by CHAMPS questionnaire * Moderate to high-risk of CHD events according to ATP-III risk classification algorithm * Willingness to be randomized to either intervention group * Willingness to participate in all study procedures

Exclusion criteria

* Failure to provide informed consent; * Regular participation in an exercise training program within the last 3 months * Absolute contraindication(s) to exercise training (American College of Sports Medicine guidelines) * Office SBP \> 180 mm Hg or DBP \> 110 mm Hg * Severe cardiac disease, i.e. NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina; * Myocardial infarction or stroke within past year * Significant cognitive impairment, i.e. known dementia or a Mini-Mental State Examination score \< 24 * Progressive, degenerative neurologic disease, e.g., Parkinson's Disease, multiple sclerosis, ALS; * Severe rheumatologic/orthopedic disease, e.g., awaiting joint replacement, active inflammatory disease * Severe pulmonary disease, requiring either steroid pills or injections or the use of supplemental oxygen; * Hip fracture, hip or knee replacement, or spinal surgery within past 4 months; * Other significant co-morbid conditions that would impair ability to participate in the intervention * Simultaneous participation in another intervention trial

Design outcomes

Primary

MeasureTime frame
Blood pressure between the groups20 weeks

Secondary

MeasureTime frameDescription
Exercise capacity between the groups20 weeksdistance on 6-minute walk test
Waist circumference between the groups20 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026